Chi-Ping Day

Chi-Ping Day

Auto-generated profile, based on publicly available information

Chi-Ping Day

Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in Science
Verified
Journal Article
Closed access
CSChristine N. Spencer
Christine N. Spencer
JMJennifer L. McQuade
Jennifer L. McQuade
VGVancheswaran Gopalakrishnan
Vancheswaran Gopalakrishnan
JMJohn A. McCulloch
John A. McCulloch
MVMarie Vetizou
Marie Vetizou
JWJennifer A. Wargo
Jennifer A. Wargo
Another benefit of dietary fiber: The gut microbiome can modulate the immune system and influence the therapeutic response of cancer patients, yet the mechanisms underlying the effects of microbiota are presently unclear. Spencer et al . add to our understanding of how dietary habits affect microbiota and clinical outcomes to immunotherapy. In an observational study, the researchers found that melanoma patients reporting high fiber (prebiotic) consumption had a better response to checkpoint inhibitor immunotherapy compared with those patients reporting a low-fiber diet. The most marked benefit was observed for those patients reporting a combination of high fiber consumption and no use of over-the-counter probiotic supplements. These findings provide early insights as to how diet-related factors may influence the immune response. —PNK

13 April 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
EPEva Pérez-Guijarro
Eva Pérez-Guijarro
HYHoward H. Yang
Howard H. Yang
RARomina E. Araya
Romina E. Araya
RMRajaa El Meskini
Rajaa El Meskini
HMHelen T. Michael
Helen T. Michael
GMGlenn Merlino
Glenn Merlino

17 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAndrea Castro
Andrea Castro
RPRachel Marty Pyke
Rachel Marty Pyke
XZXinlian Zhang
Xinlian Zhang
WTWesley Kurt Thompson
Wesley Kurt Thompson
CDChi-Ping Day
Chi-Ping Day
HCHannah Carter
Hannah Carter
Individual MHC genotype constrains the mutational landscape during tumorigenesis. Immune checkpoint inhibition reactivates immunity against tumors that escaped immune surveillance in approximately 30% of cases. Recent studies demonstrated poorer response rates in female and younger patients. Although immune responses differ with sex and age, the role of MHC-based immune selection in this context is unknown. We find that tumors in younger and female individuals accumulate more poorly presented driver mutations than those in older and male patients, despite no differences in MHC genotype. Younger patients show the strongest effects of MHC-based driver mutation selection, with younger females showing compounded effects and nearly twice as much MHC-II based selection. This study presents evidence that strength of immune selection during tumor development varies with sex and age, and may influence the availability of mutant peptides capable of driving effective response to immune checkpoint inhibitor therapy.

10 February 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JPJustine S. Paradis
Justine S. Paradis
MAMonica Acosta
Monica Acosta
RSRobert Saddawi-Konefka
Robert Saddawi-Konefka
AKAyush Kishore
Ayush Kishore
SIMONE LUBRANOSIMONE LUBRANO
SIMONE LUBRANO
JGJ.Silvio Gutkind
J.Silvio Gutkind
Purpose: Uveal melanoma is the most common eye cancer in adults. Approximately 50% of patients with uveal melanoma develop metastatic uveal melanoma (mUM) in the liver, even after successful treatment of the primary lesions. mUM is refractory to current chemo- and immune-therapies, and most mUM patients die within a year. Uveal melanoma is characterized by gain-of-function mutations in GNAQ/GNA11, encoding Gαq proteins. We have recently shown that the Gαq–oncogenic signaling circuitry involves a noncanonical pathway distinct from the classical activation of PLCβ and MEK–ERK. GNAQ promotes the activation of YAP1, a key oncogenic driver, through focal adhesion kinase (FAK), thereby identifying FAK as a druggable signaling hub downstream from GNAQ. However, targeted therapies often activate compensatory resistance mechanisms leading to cancer relapse and treatment failure.Experimental Design: We performed a kinome-wide CRISPR-Cas9 sgRNA screen to identify synthetic lethal gene interactions that can be exploited therapeutically. Candidate adaptive resistance mechanisms were investigated by cotargeting strategies in uveal melanoma and mUM in vitro and in vivo experimental systems.Results: sgRNAs targeting the PKC and MEK–ERK signaling pathways were significantly depleted after FAK inhibition, with ERK activation representing a predominant resistance mechanism. Pharmacologic inhibition of MEK and FAK showed remarkable synergistic growth-inhibitory effects in uveal melanoma cells and exerted cytotoxic effects, leading to tumor collapse in uveal melanoma xenograft and liver mUM models in vivo.Conclusions: Coupling the unique genetic landscape of uveal melanoma with the power of unbiased genetic screens, our studies reveal that FAK and MEK–ERK cotargeting may provide a new network-based precision therapeutic strategy for mUM treatment.See related commentary by Harbour, p. 2967

2 May 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YZYu Zhang
Yu Zhang
TVTrang Vu
Trang Vu
DPDouglas C. Palmer
Douglas C. Palmer
RKRigel J. Kishton
Rigel J. Kishton
LGLanqi Gong
Lanqi Gong
PJPeng Jiang
Peng Jiang

12 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMeghana Pagadala
Meghana Pagadala
TSTimothy J. Sears
Timothy J. Sears
VWVictoria H. Wu
Victoria H. Wu
EPEva Pérez-Guijarro
Eva Pérez-Guijarro
HKHyo Kim
Hyo Kim
HCHannah Carter
Hannah Carter
With the continued promise of immunotherapy for treating cancer, understanding how host genetics contributes to the tumor immune microenvironment (TIME) is essential to tailoring cancer screening and treatment strategies. Here, we study 1084 eQTLs affecting the TIME found through analysis of The Cancer Genome Atlas and literature curation. These TIME eQTLs are enriched in areas of active transcription, and associate with gene expression in specific immune cell subsets, such as macrophages and dendritic cells. Polygenic score models built with TIME eQTLs reproducibly stratify cancer risk, survival and immune checkpoint blockade (ICB) response across independent cohorts. To assess whether an eQTL-informed approach could reveal potential cancer immunotherapy targets, we inhibitCTSS, a gene implicated by cancer risk and ICB response-associated polygenic models;CTSSinhibition results in slowed tumor growth and extended survival in vivo. These results validate the potential of integrating germline variation and TIME characteristics for uncovering potential targets for immunotherapy.